American Century Companies Inc. Grows Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

American Century Companies Inc. increased its position in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 25.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 47,367 shares of the company’s stock after purchasing an additional 9,608 shares during the quarter. American Century Companies Inc.’s holdings in Shattuck Labs were worth $183,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in STTK. Cannon Global Investment Management LLC purchased a new stake in shares of Shattuck Labs during the 1st quarter valued at approximately $91,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 13.9% during the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock valued at $4,660,000 after buying an additional 63,800 shares during the period. SG Americas Securities LLC raised its position in shares of Shattuck Labs by 4.8% during the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock valued at $352,000 after buying an additional 1,788 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Shattuck Labs during the 1st quarter valued at approximately $174,000. Finally, Vanguard Group Inc. raised its position in shares of Shattuck Labs by 38.2% during the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after buying an additional 502,860 shares during the period. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Down 4.7 %

NASDAQ:STTK opened at $1.22 on Friday. The company has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $6.01. The company has a market cap of $58.01 million, a price-to-earnings ratio of -0.63 and a beta of 1.72. Shattuck Labs, Inc. has a 52 week low of $1.15 and a 52 week high of $11.76.

Shattuck Labs (NASDAQ:STTK) last issued its earnings results on Thursday, August 1st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative return on equity of 68.65% and a negative net margin of 2,067.99%. The company’s quarterly revenue was up 704.5% compared to the same quarter last year. On average, analysts expect that Shattuck Labs, Inc. will post -1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

STTK has been the topic of a number of research analyst reports. BTIG Research lowered Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Monday, June 17th. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a research report on Wednesday. Needham & Company LLC lowered Shattuck Labs from a “buy” rating to a “hold” rating and set a $8.00 target price on the stock. in a research report on Wednesday. Citigroup lowered Shattuck Labs from a “buy” rating to a “neutral” rating and cut their target price for the company from $8.00 to $2.00 in a research report on Wednesday. Finally, HC Wainwright lowered Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.67.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.